Pillstats
Rx only · Injection, Powder, For Solution · Intravenous

Imipenem And Cilastatin Sodium

Brands: Primaxin Iv · Cilastatin Sodium + Imipenem

2 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US3 NDCs
2 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
ATC—
RxCUI (US)5690
US makers2 labelers
Packages7
DEA / ScheduleNone

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

2685368041.1K2025 Q12025 Q22025 Q32025 Q42026 Q1
559
Rx · 2026 Q1
11K
Units dispensed
-40%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it2 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Fresenius Kabi USA, LLCunknown6SUPPLYING
Merck Sharp & Dohme LLC.unknown1SUPPLYING

Regulatory & supply eventsFDA · US

Shortages, recalls, and registration changes attached to this drug concept.

  • Jan 8, 2026
    RESOLVEDShortage resolved: Imipenem and Cilastatin Injection (Merck Sharp & Dohme Corp.)

    Imipenem and Cilastatin Injection — reported in shortage by Merck Sharp & Dohme Corp.. Therapeutic category: Anti-Infective.

  • Jan 8, 2026
    SHORTAGEDrug shortage: Imipenem and Cilastatin Injection (Merck Sharp & Dohme Corp.)

    Imipenem and Cilastatin Injection — reported in shortage by Merck Sharp & Dohme Corp.. Therapeutic category: Anti-Infective.